W
WAVEMAN · COMPANY
AWHL · Aspira Women'S Health Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

AWHL

Aspira Women's Health Inc.
PHARMA & BIOTECH · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · CIK 0000926617
SEC FILINGS☆ WATCH
INSIDER NET · 180D
$100.0K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
1
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
0
13F, latest reported quarter
REVENUE GROWTH
+0.4%
XBRL, annual
NET MARGIN
-138.7%
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$100.0K over 180 days
+$100.0K of it by a 10%+ holder
more than 76% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
fewer than five institutions report holding it
REVENUE
+0.4% year over year
below 53% of Pharma & Biotech
MARGIN
-138.7% net margin
below 68% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
<0.1% of shares outstanding short · 1.0 days to cover · settled 2026-07-31
below 95% of Pharma & Biotech
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -26.8%
-26.8%12M
-37%-2%+33%+68%2025-092025-102025-122026-032026-052026-072026-09 2025-09-17 · SCHULER JACK W bought $500.0K2026-06-05 · SCHULER JACK W bought $100.0K2025-09-17 · cohen Jeffrey k bought $25.0K2025-09-17 · cohen Jeffrey k bought $25.0K2025-09-17 · Fraser John D bought $7.4K2025-09-17 · Fraser John D bought $7.4K
INSIDER BUY
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders are net buyers of their own stock.
The record shows a net $100.0K bought by insiders over 180 days. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Aspira Women's Health Inc. insiders bought a net $100.0K of stock across 6 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
SCHULER JACK W
BUY
2026-06-05
222,222.0
$100.0K
SCHULER JACK W
BUY
2025-09-17
1,111,111.0
$500.0K
cohen Jeffrey k
Director
BUY
2025-09-17
55,556.0
$25.0K
Fraser John D
Director
BUY
2025-09-17
16,389.0
$7.4K
Fraser John D
Director
BUY
2025-09-17
16,389.0
$7.4K
6 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 1 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported

no 13F holders found for this ticker

SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Clinical pipeline
ClinicalTrials.gov · 3 registered trials, 1 still enrolling or running — a status change here is dated weeks before the press release
3
Not applicable
1 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$9.2M$9.2M$9.2M$8.2M
GROSS PROFIT$5.9M$5.5M$5.3M$4.3M
OPERATING INCOME$-7.9M$-16.3M$-18.9M$-31.1M
NET INCOME$-12.8K$-13.1K$-17.0K$-29.9M
EPS (DILUTED)-0.37-0.93-1.81-3.85
OPERATING CASH FLOW$-7.0M$-12.1M$-15.9M$-31.1M
CASH$1.8M$1.8M$2.6M$13.3M
LONG-TERM DEBT$1.0M$1.3M$1.4M$2.3M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →